Baltimore settles with Teva, Walgreens ahead of scheduled opioid trial
By Brendan Pierson
Sept 10 (Reuters) -Baltimore said on Tuesday that it has settled with Walgreens WBA.O over claims that the pharmacy operator fueled opioid addiction in the Maryland city, the latest in a series of settlements totaling $402.5 million ahead of a trial scheduled to begin next week.
The announcement came a day after the city reached an $80 million settlement over opioids with drugmaker Teva Pharmaceutical TEVA.TA. Baltimore did not disclose the terms of its settlement with Walgreens, but the cumulative settlement amount implies that it was also $80 million.
"We are proud of our efforts to bring these companies to justice over the past several years," Baltimore Mayor Brandon Scott said in a statement.
"Although Walgreens strongly disputes any liability, this settlement is in the best interests of all of our stakeholders," Walgreens said in a statement.
The remaining defendants scheduled to face trial next week are drugmaker Johnson & Johnson JNJ.N, and distributors McKesson MCK.N and Cencora COR.N. Teva and the remaining defendants did not immediately respond to requests for comment.
Baltimore earlier this year announced settlements with drugmaker AbbVie's ABBV.N Allergan unit, pharmacy operator CVS CVS.N and drug distributor Cardinal Health CAH.N.
Like more than 3,000 other local governments that have filed lawsuits over opioids, the city accused drugmakers of downplaying opioids' addiction risks, and distributors and pharmacies of ignoring red flags that pills were being diverted into illegal channels.
The vast majority of those cases have been settled through nationwide agreements, which now total about $46 billion.
Baltimore opted against joining those global settlements in the hopes of recovering even more than what it would have received through those deals. The city said that under a multi-state settlement with Teva, for example, it would have received only $11 million over 13 years.
More than 800,000 people in the United States died of opioid overdoses from 1999 through 2023, according to data from the U.S. Centers for Disease Control and Prevention.
Reporting By Brendan Pierson in New York, Editing by Alexia Garamfalvi and Jonathan Oatis
Aset Berkaitan
Berita Terkini
Penafian: Entiti XM Group menyediakan perkhidmatan pelaksanaan sahaja dan akses ke Kemudahan Dagangan Atas Talian, yang membolehkan sesorang melihat dan/atau menggunakan kandungan yang ada di dalam atau melalui laman web, tidak bertujuan untuk mengubah atau memperluas, juga tidak mengubah atau mengembangkannya. Akses dan penggunaan tersebut tertakluk kepada: (i) Terma dan Syarat; (ii) Amaran Risiko; dan Penafian Penuh. Oleh itu, kandungan sedemikian disediakan tidak lebih dari sekadar maklumat umum. Terutamanya, perlu diketahui bahawa kandungan Kemudahan Dagangan Atas Talian bukan permintaan, atau tawaran untuk melakukan transaksi dalam pasaran kewangan. Berdagang dalam mana-mana pasaran kewangan melibatkan tahap risiko yang besar terhadap modal anda.
Semua bahan yang diterbitkan di Kemudahan Dagangan Atas Talian kami bertujuan hanya untuk tujuan pendidikan/maklumat dan tidak mengandungi – dan tidak boleh dianggap mengandungi nasihat kewangan, cukai pelaburan atau dagangan dan cadangan, atau rekod harga dagangan kami, atau tawaran, atau permintaan untuk suatu transaksi dalam sebarang instrumen kewangan atau promosi kewangan yang tidak diminta kepada anda.
Sebarang kandungan pihak ketiga serta kandungan yang disediakan oleh XM, seperti pendapat, berita, penyelidikan, analisis, harga, maklumat lain atau pautan ke laman web pihak ketiga yang terdapat dalam laman web ini disediakan berdasarkan "seadanya" sebagai ulasan pasaran umum dan bukanlah nasihat pelaburan. Sesuai dengan apa-apa kandungan yang ditafsir sebagai penyelidikan pelaburan, anda mestilah ambil perhatian dan menerima bahawa kandungan tersebut tidak bertujuan dan tidak sediakan berdasarkan keperluan undang-undang yang direka untuk mempromosikan penyelidikan pelaburan bebas dan oleh itu, ia dianggap sebagai komunikasi pemasaran di bawah peraturan dan undang-undang yang berkaitan. SIla pastikan bahawa anda telah membaca dan memahami Notifikasi mengenai Penyelidikan Pelaburan Bukan Bebas dan Amaran Risiko mengenai maklumat di atas yang boleh diakses di sini.
